Clinical Trial Update: The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the efficacy and safety of bortezomib for relapsed/refractory immune thrombocytopenia and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Relapsed/Refractory Immune Thrombocytopenia | Phase 2 | Status: RECRUITING